Liquidia stock
LQDANASDAQLiquidia Corporation, HealthcareISIN US53635D2027
43Score 43 out of 100, Weak
Price and trend
64 / 100
Price history
+105% in one yearThe chart shows daily closes over 8 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 6.4% above it.
Since October 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Overheated: the price has risen very quickly lately (RSI 76).
The price is 36% below its 52-week high. Largest decline in 8 years: 94% (October 2018 to August 2021).
Chart figures for advanced users
- SMA 50$49.19
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$54.64
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)76
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$25.91
- The lowest closing price of the last twelve months.
- Resistance$91.03
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Liquidia Corporation belongs to the Medical (Pharmaceuticals) industry (United States) and, with a market value of $5.24B, is number 12 of 15 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $158.32M (up 1,031.2% year on year) and a loss of $68.92M.
- For fiscal 2026, analysts expect on average revenue of $717M (up 352.9%) and adjusted earnings per share of $2.03.
Show more
- MEQIRI Score 43 out of 100 (Weak): rank 492 of 702 in Healthcare, median 53.
- Our model puts fair value at $60.82, with the price 4% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 192.5% a year since 2020, Medical (Pharmaceuticals) median 12.8%.Growth 70
- More cash than debtCash $396.09M, financial debt $168.76M.
Weaknesses
- DilutionShare count up 154% since 2020.Capital allocation 18
- Loss-makingLoss of $94.19M over the last 12 months.Fundamentals 17
- Volatile share priceVolatility 93% a year over the last 12 months.Stability 16
Its standout strengths are momentum and growth, while fundamentals and stability hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- weak fundamentals
- high price swings
- price up very strongly over the past year
Valuation
Valuation signal
Fairly valuedIn our model the price counts as cheap below $40.54 and expensive above $121.63 (uncertainty very high, based on the price swings of the past year).
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $52.68, at 7.8% it would be $72.91.
Valuation metrics
From the cash-flow model alone; without earnings there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
Revenue has grown strongly since 2016, at around 32% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 92%, operating −32%, net −44%. Last 12 months: net −15%.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 4 Mar 2027in 111 days
- Last reported
- 10 Nov 2026EPS reported −$2.64 (expected $0.96)below expectations
Analyst estimates
Analysts have cut their 2026 earnings estimate by 3.1% since 15 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- $2.03−3.1%
- Revenue
- $717M0.0%
- Earnings per share
- $2.190.0%
- Revenue
- $762.18M0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: −18.1%Continued revenue and profit growth expected, research costs in the second half are expected to be double the first half; no guidance change.
“More specifically, we expect R&D expense in the second half of 2026 to be double the expense in the first half of the year and to increase again in 2027 as we build the best inhaled treprostinil products for future and current patients.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 12 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 13 insiders sold, $163.22M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Boyle DanaSale
26 Oct 2026, Chief Accounting Officer
- Shares
- 1,581
- Price
- $43.19
- Value
- $68,283
- Adair JasonSale
26 Oct 2026, Chief Business Officer
- Shares
- 688
- Price
- $43.19
- Value
- $29,715
- Schundler RussellSale
12 Oct 2026, General Counsel
- Shares
- 13,692
- Price
- $28.48
- Value
- $389,948
Show 59 more
- Saggar RajeevSale
12 Oct 2026, Chief Medical Officer
- Shares
- 9,218
- Price
- $28.48
- Value
- $262,529
- Moomaw ScottSale
12 Oct 2026, Chief Commercial Officer
- Shares
- 8,863
- Price
- $28.48
- Value
- $252,418
- Krepp SarahSale
12 Oct 2026, Chief Human Resource Officer
- Shares
- 5,245
- Price
- $28.48
- Value
- $149,378
- Khindri SanjeevSale
12 Oct 2026, Chief Development Officer
- Shares
- 1,101
- Price
- $28.48
- Value
- $31,356
- Kaseta MichaelSale
12 Oct 2026, CFO and COO
- Shares
- 18,938
- Price
- $28.48
- Value
- $539,354
- Jeffs RogerSale
12 Oct 2026, Chief Executive Officer
- Shares
- 32,744
- Price
- $28.48
- Value
- $932,549
- Boyle DanaSale
12 Oct 2026, Chief Accounting Officer
- Shares
- 5,892
- Price
- $28.48
- Value
- $167,804
- Adair JasonSale
12 Oct 2026, Chief Business Officer
- Shares
- 7,301
- Price
- $28.48
- Value
- $207,932
- Bloch Stephen MSale
5 Oct 2026, Board
- Shares
- 235,477
- Price
- $27.13
- Value
- $6.39M
- Singh RamanSale
14 Sept 2026, Board
- Shares
- 8,468
- Price
- $66.16
- Value
- $560,243
- Singh RamanSale
11 Sept 2026, Board
- Shares
- 9,024
- Price
- $68.62
- Value
- $619,210
- Krepp SarahSale
1 Sept 2026, Chief Human Resource Officer
- Shares
- 274
- Price
- $67.76
- Value
- $18,566
- Adair JasonSale
21 Aug 2026, Chief Business Officer
- Shares
- 73,631
- Price
- $69.09
- Value
- $5.09M
- Rielly-Gauvin KatherineSale
20 Aug 2026, Board
- Shares
- 18,393
- Price
- $72.23
- Value
- $1.33M
- Rielly-Gauvin KatherineSale
19 Aug 2026, Board
- Shares
- 36,789
- Price
- $74.99
- Value
- $2.76M
- Saggar RajeevSale
19 Aug 2026, Chief Medical Officer
- Shares
- 50,000
- Price
- $74.06
- Value
- $3.7M
- Saggar RajeevSale
17 Aug 2026, Chief Medical Officer
- Shares
- 29,534
- Price
- $76.84
- Value
- $2.27M
- Boyle DanaSale
27 Jul 2026, Chief Accounting Officer
- Shares
- 1,600
- Price
- $87.53
- Value
- $140,048
- Adair JasonSale
27 Jul 2026, Chief Business Officer
- Shares
- 688
- Price
- $87.53
- Value
- $60,221
- Bloch Stephen MSale
23 Jul 2026, Board
- Shares
- 100,000
- Price
- $89.48
- Value
- $8.95M
- Bloch Stephen MSale
22 Jul 2026, Board
- Shares
- 100,000
- Price
- $88.38
- Value
- $8.84M
- Bloch Stephen MSale
21 Jul 2026, Board
- Shares
- 75,000
- Price
- $79.99
- Value
- $6M
- Bloch Stephen MSale
20 Jul 2026, Board
- Shares
- 3,596
- Price
- $79.55
- Value
- $286,068
- Krepp SarahSale
13 Jul 2026, Chief Human Resource Officer
- Shares
- 7,864
- Price
- $71.51
- Value
- $562,361
- Khindri SanjeevSale
13 Jul 2026, Chief Development Officer
- Shares
- 1,185
- Price
- $71.51
- Value
- $84,740
- Kaseta MichaelSale
13 Jul 2026, CFO and COO
- Shares
- 20,430
- Price
- $71.51
- Value
- $1.46M
- Jeffs RogerSale
13 Jul 2026, Chief Executive Officer
- Shares
- 35,249
- Price
- $71.51
- Value
- $2.52M
- Adair JasonSale
13 Jul 2026, Chief Business Officer
- Shares
- 7,863
- Price
- $71.51
- Value
- $562,289
- Schundler RussellSale
13 Jul 2026, General Counsel
- Shares
- 14,738
- Price
- $71.51
- Value
- $1.05M
- Saggar RajeevSale
13 Jul 2026, Chief Medical Officer
- Shares
- 9,926
- Price
- $71.51
- Value
- $709,816
- Moomaw ScottSale
13 Jul 2026, Chief Commercial Officer
- Shares
- 9,539
- Price
- $71.51
- Value
- $682,142
- Boyle DanaSale
13 Jul 2026, Chief Accounting Officer
- Shares
- 9,002
- Price
- $71.51
- Value
- $643,740
- Bloch Stephen MSale
7 Jul 2026, Board
- Shares
- 50,000
- Price
- $80.94
- Value
- $4.05M
- Bloch Stephen MSale
6 Jul 2026, Board
- Shares
- 25,000
- Price
- $80.18
- Value
- $2M
- Bloch Stephen MSale
1 Jul 2026, Board
- Shares
- 25,000
- Price
- $79.47
- Value
- $1.99M
- Bloch Stephen MSale
22 Jun 2026, Board
- Shares
- 100,000
- Price
- $75.74
- Value
- $7.57M
- Bloch Stephen MSale
15 Jun 2026, Board
- Shares
- 85,062
- Price
- $71.44
- Value
- $6.08M
- Bloch Stephen MSale
12 Jun 2026, Board
- Shares
- 111,049
- Price
- $71.46
- Value
- $7.94M
- Krepp SarahSale
11 Jun 2026, Chief Human Resource Officer
- Shares
- 24,880
- Price
- $70.28
- Value
- $1.75M
- Bloch Stephen MSale
11 Jun 2026, Board
- Shares
- 242,269
- Price
- $70.43
- Value
- $17.06M
- Bloch Stephen MSale
10 Jun 2026, Board
- Shares
- 145,954
- Price
- $65.58
- Value
- $9.57M
- Bloch Stephen MSale
9 Jun 2026, Board
- Shares
- 72,534
- Price
- $64.38
- Value
- $4.67M
- Khindri SanjeevSale
8 Jun 2026, Chief Development Officer
- Shares
- 4,134
- Price
- $65.46
- Value
- $270,612
- Bloch Stephen MSale
8 Jun 2026, Board
- Shares
- 148,301
- Price
- $64.76
- Value
- $9.6M
- Bloch Stephen MSale
5 Jun 2026, Board
- Shares
- 2,064
- Price
- $64.14
- Value
- $132,384
- Manning Paul BSale
4 Jun 2026, Board
- Shares
- 200,000
- Price
- $63.91
- Value
- $12.78M
- Bloch Stephen MSale
4 Jun 2026, Board
- Shares
- 82,736
- Price
- $64.97
- Value
- $5.38M
- Jeffs RogerSale
27 May 2026, Chief Executive Officer
- Shares
- 6,428
- Price
- $62.18
- Value
- $399,712
- Jeffs RogerSale
26 May 2026, Chief Executive Officer
- Shares
- 25,000
- Price
- $60.38
- Value
- $1.51M
- Jeffs RogerSale
22 May 2026, Chief Executive Officer
- Shares
- 25,000
- Price
- $61.52
- Value
- $1.54M
- Singh RamanSale
21 May 2026, Board
- Shares
- 29,494
- Price
- $60.13
- Value
- $1.77M
- Jeffs RogerSale
21 May 2026, Chief Executive Officer
- Shares
- 25,000
- Price
- $61.13
- Value
- $1.53M
- Jeffs RogerSale
20 May 2026, Chief Executive Officer
- Shares
- 25,000
- Price
- $61.30
- Value
- $1.53M
- Caligan Partners LPPurchase
19 May 2026, Board
- Shares
- 5,300
- Price
- $59.98
- Value
- $317,894
- Caligan Partners LPSale
19 May 2026, Board
- Shares
- 5,300
- Price
- $59.98
- Value
- $317,894
- Jeffs RogerSale
19 May 2026, Chief Executive Officer
- Shares
- 25,000
- Price
- $58.65
- Value
- $1.47M
- Jeffs RogerSale
18 May 2026, Chief Executive Officer
- Shares
- 25,000
- Price
- $56.77
- Value
- $1.42M
- Jeffs RogerSale
15 May 2026, Chief Executive Officer
- Shares
- 25,000
- Price
- $57.04
- Value
- $1.43M
- Jeffs RogerSale
14 May 2026, Chief Executive Officer
- Shares
- 25,000
- Price
- $58.62
- Value
- $1.47M
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Liquidia
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 43
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Pharmaceuticals)
The next larger and next smaller companies by market value
- Corcept TherapeuticsCORT $8.07B75
- Kiniksa Pharmaceuticals InternationalKNSA $7.56B68
- Tsuruha Holdings3391.T $7.1B62
- MatsukiyoCocokara3088.T $6.71B75
- Abbott IndiaABBOTINDIA.NS $6.01B75
- Prestige Consumer HealthcarePBH $2.15B56
- CosmoCMHC.SW $1.21B37
- SwedencareSECARE.ST $312.54M51
ETFs that hold Liquidia
Held by 13 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares S&P SmallCap 600 UCITS ETFIUS3 | 0.23% | 0.30% | €2.31B |
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.20% | 0.30% | €185.82M |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.12% | 0.30% | €4.28B |
Show 5 more
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.11% | 0.30% | €2.22B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.06% | 0.43% | €2.5B |
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.03% | 0.45% | €1.54B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.03% | 0.10% | €395.74M |
| UBS MSCI USA Select Factor Mix UCITS ETF USD accUSUE | 0.01% | 0.25% | €178.55M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak since 11 Nov 2026, previously Neutral
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.